ArticlePLOS global public health2024

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Vimla Naicker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.